The English NHS has given the green light to a new drug, mirvetuximab, designed to combat ovarian cancer resistant to conventional treatments. It acts like a guided missile: it delivers chemotherapy directly to tumor cells, minimizing collateral damage to healthy tissues. A strategy that promises to change the landscape for patients with limited options.
Precision engineering: how the antibody-drug conjugate works 🧬
Mirvetuximab belongs to the family of antibody-drug conjugates (ADCs). The antibody recognizes a specific protein, FRα, overexpressed in many ovarian tumors. Upon binding, it releases a potent chemotherapy payload directly inside the cancer cell. This approach allows the use of high drug doses without exposing the rest of the body, reducing side effects such as nausea or neuropathy. A solid technical advance for difficult tumors.
Guided missile, but without GPS: what happens when the tumor moves 🎯
The concept is elegant: a biological missile that only explodes where it should. Too bad that cancer, like a noisy neighbor, sometimes changes address without warning. If the tumor stops expressing FRα, the drug is left like a lost tourist in the body. But as long as it works, it is a relief for those who have tried everything and now receive chemo with a personalized escort.